FDA ApprovedUnited States
New Oral Treatment for Multiple Myeloma After Prior Therapy
Zenbexus (iberdomide) — first labelled CELMoD for adults with multiple myeloma after ≥1 prior line
FDA accelerated approval on 13 August 2026 for Zenbexus (iberdomide) capsules — an oral cereblon-modulating protein degrader (CELMoD) — in combination with…
This is for adults with multiple myeloma who have already had at least one prior treatment that included a proteasome inhibitor and an immunomodulatory drug…